Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases.

Clara UdaondoCarmen CámaraLaura Miguel BerenguelRosa Alcobendas RuedaCelia Muñoz GómezClaudia Millán LongoBlanca Díaz-DelgadoIker Falces-RomeroMariana Díaz AlmirónJordi OchandoAna Méndez-EchevarríaAgustín Remesal CambaCristina Calvo

Published in: Pediatric rheumatology online journal (2022)

We conclude that standard of care treatment for adolescents with RD including TNF inhibitors and methotrexate did not affect the humoral and the cellular immunity to BNT162b2 mRNA vaccination compared to a healthy control group. The previous contact with SARS-CoV-2 was the most relevant factor in the immune response.

Keyphrases

immune response
sars cov
young adults
respiratory syndrome coronavirus
physical activity
dendritic cells
toll like receptor
healthcare
rheumatoid arthritis
palliative care
binding protein
high dose
quality improvement
inflammatory response
low dose
combination therapy
coronavirus disease